Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

June 06, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas to Present at the Goldman Sachs 40th Annual Global Healthcare Conference

NEW HAVEN, Conn., June 06, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that Ian Taylor,...
June 04, 2019 07:00 ET | Source: Arvinas Inc.

Bayer and Arvinas to Collaborate on Human PROTAC® Therapies and Launch a Separate Joint Venture to Develop Agricultural PROTAC® Applications

- $110M+ life sciences deal to develop novel PROTAC® candidates for patients with cardiovascular, oncological, and gynecological diseases, and to expand application of PROTAC® degraders to plant...
May 29, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Receives Fast Track Designation for its Targeted Protein Degrader ARV-110 as a Treatment for Men with Metastatic Castration-Resistant Prostate Cancer

NEW HAVEN, Conn., May 29, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today announced...
May 08, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Reports First Quarter Financial Results and Provides Corporate Update

NEW HAVEN, Conn., May 08, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, today reported...
April 02, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Strengthens Management Team with Internal Appointments of Andy Crew, Ph.D. as Chief Technology Officer and Ian Taylor, Ph.D. as Chief Scientific Officer

NEW HAVEN, Conn., April 02, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrades disease-causing proteins, announced...
March 26, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Reports Fourth Quarter and Full Year 2018 Financial Results and Provides Corporate Update

NEW HAVEN, Conn., March 26, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today reported...
March 25, 2019 07:00 ET | Source: Arvinas Inc.

Arvinas Announces Initiation of Patient Dosing in the First Phase 1 Clinical Trial of PROTAC™ Protein Degrader, ARV-110

NEW HAVEN, Conn., March 25, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biopharmaceutical company creating a new class of therapies that degrade disease-causing proteins, today...
February 07, 2019 16:30 ET | Source: Arvinas Inc.

Arvinas Announces Poster Presentation at ASCO 2019 Genitourinary Cancers Symposium

NEW HAVEN, Conn., Feb. 07, 2019 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on protein degradation, today announced that it will...
January 04, 2019 17:00 ET | Source: Arvinas Inc.

Arvinas Receives Authorization to Proceed for its IND Application for PROTAC™ Therapy to Treat Patients with Metastatic Castration-Resistant Prostate Cancer

NEW HAVEN, Conn., Jan. 04, 2019 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that...
December 07, 2018 19:00 ET | Source: Arvinas Inc.

Arvinas Presents Preclinical Data on Protein Degrader, ARV-471, at the 2018 San Antonio Breast Cancer Symposium (SABCS)

NEW HAVEN, Conn., Dec. 07, 2018 (GLOBE NEWSWIRE) -- Arvinas Inc. (Nasdaq: ARVN), a biotechnology company creating a new class of drugs based on targeted protein degradation, today presented positive...